Updates are available Correction dated 2025-03-26
Click to view Correction: https://doi.org/10.1038/s41408-025-01243-7
-
Authors
Mukhopadhyay, Pralay
Abdullah, Hesham A.
Opalinska, Joanna B.
Paka, Prani
Richards, Eric
Weisel, Katja https://orcid.org/0000-0001-9422-6614
Trudel, Suzanne
Mateos, Maria-Victoria https://orcid.org/0000-0003-2390-1218
Dimopoulos, Meletios Athanasios https://orcid.org/0000-0001-8990-3254
Lonial, Sagar https://orcid.org/0000-0002-8322-9323
- License Information
-
More Information
Article History
Received: 25 October 2024
Revised: 13 December 2024
Accepted: 14 January 2025
First Online: 7 February 2025
Change Date: 28 February 2025
Change Type: Update
Change Details: The original online version of this article was revised: In the figure, it appears that the timeline schema incorrectly says: “<b>BVd</b> vs PVd” under the DREAMM-8 trial, instead of “<b>BPd</b> vs PVd”. Additionally, we note that the arrow under the DREAMM-7 trial indicating the PCA should be at the end of 2023 rather than at the end of 2022.
Change Date: 26 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-025-01243-7
Competing interests
: PM, HAA, JBO, PP, and ER are employees of, and hold financial equities in GSK. SL reports grant funding and personal fees from Celgene and Takeda and personal fees from Novartis, Bristol-Myers Squibb, GSK, Amgen, Merck, and Janssen. KW has received honoraria from Abbvie, Amgen, Adaptive Biotech, AstraZeneca, BMS/Celgene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline, and Takeda; consulting or advisory fees from Abbvie, Amgen, Adaptive Biotech, BMS/Celgene, Janssen, GSK, Karyopharm, Oncopeptides, Pfizer, Roche Pharma, Sanofi, and Takeda, and research funding from Abbvie, Amgen, BMS/Celgene, Janssen, GSK, and Sanofi. ST has received honoraria from Amgen Canada, Janssen Biotech, Pfizer, and Sanofi; has received grant funding from Amgen Inc, and Bristol-Myers Squibb, and has received research funding from Bristol-Myers Squibb, Genentech, GSK, Janssen, Pfizer and Roche; has acted as a consultant for Bristol-Myers Squibb, GSK, Roche, and Sanofi. MVM has received speakers fees from Amgen, Celgene, GSK, Janssen, Pfizer, Sanofi Pasteur, Takeda Oncology; participated in advisory boards for Celgene, GSK, Janssen, Pfizer, Regeneron Pharmaceuticals, and Sanofi Pasteur, and acted as a consultant for Hoffmann-La Roche, Kite Pharma, and Stemline Therapeutics. MAD has received fees from speaker’s bureau participation from Amgen, Beigene, BMS, Janssen, and Takeda.
